Navigation Links
NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
Date:5/16/2012

ver a 24-hour period compared to placebo with a fast onset of action at first dose, as well as improving exercise endurance. It was submitted for regulatory approval in Europe in Q3 2011 and Japan in Q4 2011, and expected US filing is in the beginning of 2014. NVA237 was licensed to Novartis in April 2005 by Sosei and our co-development partner Vectura.

Indacaterol (Onbrez® Breezhaler®) is Novartis' once daily long acting beta2-agonist (LABA). Novartis received European regulatory approval for 150 mcg and 300 mcg once-daily doses, under the brand name Onbrez® Breezhaler® in November 2009. In July 2011, Novartis announced approval of the 75 mcg once-daily dose in the US under the brand name Arcapta™ Neohaler™, and of the 150 mcg once-daily dose in Japan under the brand name Onbrez® Inhalation Capsules.

QVA149 (indacaterol 110 mcg/glycopyrronium bromide 50 mcg) is an investigational inhaled, once-daily, fixed dose combination of the long acting beta2-agonist (LABA) indacaterol, and the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide (NVA237). The first four QVA149 Phase III studies in the treatment of COPD all met their primary endpoints. The results of the SHINE, BRIGHT, ENLIGHTEN and ILLUMINATE studies, which are key components of the IGNITE program, demonstrate the potential of QVA149 in the treatment of COPD. Filing for QVA149 in Europe is expected in Q4 2012.

About COPD

COPD is a progressive disease associated mainly with tobacco smoking, air pollution or occupational exposure, which can cause obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness. It affects an estimated 210 million people worldwide[1]and is predicted to be the third leading cause of death by 2020[2]. Although COPD is often thought of as a disea
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress
2. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
3. Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
4. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
5. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
6. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
7. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
9. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
10. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... LONDON , April 21, 2015 ... for Enterprise, having achieved dazzling export-led growth in ... London™ today celebrates its part in winning the ... International Trade, awarded to Oxford PharmaGenesis. As part ... London helps its clients bring new medicines to ...
(Date:4/21/2015)... -- This report analyzes the worldwide markets for Apheresis ... for Therapeutic Apheresis, and Equipment for Donor Apheresis. Global ... Plateletpheresis, and Others. The report provides separate comprehensive analytics ... Japan , Europe , ... Annual estimates and forecasts are provided for the period ...
(Date:4/21/2015)... -- Cardiologists at Henry Ford Hospital have implanted a device ... irregular heartbeat. With only handful of hospitals in ... able to add another option to its arsenal of tools ... ability to pump. "This is a first ... implant at a non-clinical trial site," says cardiologist Claudio ...
Breaking Medicine Technology:Queen's Award Crowns Achievements of Fast-growing London Consultancy 2Queen's Award Crowns Achievements of Fast-growing London Consultancy 3Queen's Award Crowns Achievements of Fast-growing London Consultancy 4Queen's Award Crowns Achievements of Fast-growing London Consultancy 5World Apheresis Equipment Industry 2World Apheresis Equipment Industry 3World Apheresis Equipment Industry 4World Apheresis Equipment Industry 5World Apheresis Equipment Industry 6World Apheresis Equipment Industry 7World Apheresis Equipment Industry 8World Apheresis Equipment Industry 9World Apheresis Equipment Industry 10World Apheresis Equipment Industry 11World Apheresis Equipment Industry 12World Apheresis Equipment Industry 13World Apheresis Equipment Industry 14World Apheresis Equipment Industry 15World Apheresis Equipment Industry 16World Apheresis Equipment Industry 17World Apheresis Equipment Industry 18World Apheresis Equipment Industry 19World Apheresis Equipment Industry 20World Apheresis Equipment Industry 21Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 2Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 3
(Date:4/21/2015)... (PRWEB) April 21, 2015 Top medical ... in India for their ongoing commitment to providing superior ... strives to provide patients with the best possible experience ... skin, hair and body. , Executives at Ojas Aesthetic ... the philosophy of — nothing about you, without you ...
(Date:4/21/2015)... Jersey City, NJ (PRWEB) April 21, 2015 ... enterprise collaboration across platforms and devices, today announced a ... the integration of the new Microsoft Office 365 Management ... that allows customers to fully audit and take action ... 365 environments. , “The new Office 365 Management Activity ...
(Date:4/21/2015)... WA (PRWEB) April 21, 2015 ... Practice Edition 2 for otolaryngologists, bringing the most ... the healthcare community. Otolaryngologists can now experience ... by a trusted source in the industry, Lyft, ... integration with leading EHRs. , “Lyft is very ...
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 Edward ... and Arthur “A.G.” Kawamura, former Secretary of the California ... featured speakers for the 2nd Annual GrowRIVERSIDE Conference: The ... , The inclusion of these nationally known experts ... experts, city planners, farmers and others slated to speak ...
(Date:4/21/2015)... Further strengthening ties between the two institutions, ... goods and services to the University of South Florida ... BRIDGE Healthcare Clinic. , The BRIDGE clinic – a ... year – provides primary medical care to more than ... inside the USF Health Morsani Center for Advanced Healthcare. ...
Breaking Medicine News(10 mins):Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 2Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 3Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 2Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 3Health News:Lyft Expands Its Offerings to Include Dragon® Medical Practice Edition 2 for Otolaryngologists. 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 3Health News:USF Health and Florida Hospital Tampa Partner to Expand BRIDGE Clinic 2Health News:USF Health and Florida Hospital Tampa Partner to Expand BRIDGE Clinic 3
... the insulin gene to diabetes patients using nanoparticles, was presented ... Society of Gene Therapy (ASGT) in Seattle. ,Type ... the insulin producing pancreatic -cells. As a result of the ... damage to fine blood vessels and nerve endings leading to ...
... with culture-positive tuberculosis (TB), relapse rates were found ... compared to HIV-uninfected patients following a rifamycin-based regimen. ... patients who received intermittent or standard 6-month therapy ... treatment. ,The results appear in the ...
... But one should pop the pill just before sex. The ... good news for those suffering from erectile dysfunction (ED) - ... than the pills. ,Human and animal trials suggest ... treatments available. A University of Pittsburgh team, led by Dr ...
... CHICAGO:- Scientific advances have enabled better diagnosis and treatment ... presented at the world's premier conference on cancer. "We've ... unique to women," Julie Gralow, assistant professor of oncology ... ,"The studies discussed today bring us even closer ...
... CHICAGO, Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, ... extended overall survival in patients with hepatocellular ... taking placebo by 44%. Results were presented at ... of Clinical Oncology (ASCO). ,The international, ...
... new climate plan of the US should complement rather than ... Climate Change (UNFCCC), China's top economic planner Ma Kai ... common but differentiated responsibilities in the UNFCCC and some details ... other countries, Ma said at a press conference. ...
Cached Medicine News:Health News:Novel Delivery Method of Insulin Gene to Combat Juvenile Diabetes Developed 2Health News:Treatment Outcomes of Patients With HIV and Tuberculosis 2Health News:Gene Therapy a Better Alternative to Viagra Please 2Health News:Advanced Scientific Brings Help for Breast Cancer Survivors 2Health News:Nexavar Significantly Extends Survival of Liver Cancer Patients 2
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTP/1Q-PAL chairs are recommended for the ... room, static control, health care and ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With polished ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTN/1Q-CAB chairs are recommended for ... clean room, static control, health care ...
Medicine Products: